Mass Tort brief
Daubert Tests, MDL Carve-Outs, and New Toxic Frontiers
Federal courts test expert science across 4,000 GLP-1 claims as new dockets organize around firefighter gear, pesticides, and AI datacenter pollution.
Mass Tort
Federal Daubert hearings will decide if expert science survives in the 4,000-case GLP-1 docket — making or breaking bellwether trials against Novo Nordisk and Eli Lilly.
BackgroundMultidistrict litigation centralizes thousands of federal product liability lawsuits before a single judge to streamline pretrial evidence and conduct test trials. Under Rule 702 Daubert standards, judges act as gatekeepers to exclude expert scientific testimony that lacks rigorous methodological backing.
- The MDL docket in Philadelphia surpassed 4,022 active federal personal injury actions against drug manufacturers, creating immense financial exposure for top pharmaceutical companies.
- Novo Nordisk and Eli Lilly argue that gastrointestinal symptoms are well-documented, transient side effects already disclosed on warning labels rather than permanent unlisted injuries.
- A parallel MDL docket covering over 216 claims alleging nonarteritic anterior ischemic optic neuropathy vision loss is consolidating separately, threatening a second front of trial risk.
Mass Tort
A $40M jury verdict for a fractured heart catheter shifted momentum in the Bard PowerPort MDL — pressuring Becton Dickinson toward global settlement talks.
BackgroundImplantable port catheters are surgically placed beneath the skin to deliver chemotherapy and intravenous medications directly into large veins. Lawsuits allege that Bard manufactured ports using polyurethane prone to micro-cracks, causing catheter fragments to break off into critical vascular chambers.
- The $40M jury award followed an initial defense verdict for Bard in an earlier bellwether trial that focused strictly on catheter-related infection claims.
- Over 3,700 actions are pending before Judge David Campbell in Phoenix alleging defective device design and failure to warn of life-threatening fracture risks.
- The substantial damages award increases financial pressure on parent company Becton Dickinson to initiate comprehensive global settlement talks before additional trials begin.
Mass Tort
The JPML carved firefighter gear into a dedicated MDL — creating a separate liability track for chemical makers outside the crowded firefighting foam docket.
BackgroundPer- and polyfluoroalkyl substances, known as forever chemicals, are synthetic compounds widely used in industrial textiles to repel extreme heat and moisture. Firefighters allege that turnout clothing contains heavy chemical concentrations that degrade under heat and absorb directly through skin during emergency responses.
- U.S. District Judge Jeffrey M. Bryan in Minnesota will oversee discovery into protective equipment manufacturers and chemical producers including 3M and DuPont.
- The new MDL consolidates economic loss and personal injury claims brought by municipal fire departments, labor unions, and individual firefighters suffering from occupational cancers.
- Decoupling the turnout gear docket from the AFFF foam litigation allows plaintiffs to target equipment makers directly without waiting for water utility settlements to clear.
Mass Tort
Mead Johnson secured a complete defense verdict in the first federal NEC bellwether — demonstrating jurors will reject formula warnings claims.
BackgroundNecrotizing enterocolitis is a severe, life-threatening intestinal inflammation that strikes premature infants fed cow's milk formula rather than human donor milk. The federal multidistrict litigation consolidates hundreds of actions against Mead Johnson and Abbott Laboratories alleging manufacturers concealed bowel disease risks.
- The complete defense verdict in Inman v. Mead Johnson halted plaintiff momentum following massive state court jury awards against formula makers in Missouri and Illinois.
- Abbott Laboratories previously agreed to an aggregate $670M settlement resolving roughly 2,000 infant injury claims and a $495M verdict, illustrating the volatile stakes.
- More than 800 coordinated federal actions remain pending before U.S. Senior District Judge Rebecca Pallmeyer in Chicago as plaintiff leadership reassesses trial strategy.
Mass Tort
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
